Condition: NSTEMI - Non-ST Segment Elevation MI · STEMI (ST Elevation MI) · Myocardial Infarction · Sponsor: Montreal Heart Institute
In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.
This description comes directly from the study's public registry record.
Guillaume Marquis-Gravel, MD · 1-514-376-3330 · guillaume.marquis.gravel@umontreal.ca
Roseline Therrien · 1-514-461-1300 · roseline.therrien@seriant.org
Always discuss trial participation with your own doctor first.
| Montreal Heart Institute | Montreal, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07257198